Excessive Daytime Sleepiness and Your Genetics
Written by Scott Peeples, BS Biomedical Sciences · ExomeDNA Founder
Research base: Moderate.
What is HLA-DQB1*06:02 negative hypersomnia?
Hypersomnia refers to excessive daytime sleepiness or prolonged nighttime sleep that interferes with daily functioning despite adequate opportunity for sleep. Several distinct conditions fall under the hypersomnia umbrella, and understanding which biological subtype is being studied requires attention to the HLA markers used to define the cohort.
HLA-DQB106:02 is an allele of the human leukocyte antigen class II system that is present in more than 95% of narcolepsy type 1 (NT1) patients. NT1 is caused by autoimmune destruction of hypothalamic hypocretin (orexin) neurons, and the HLA-DQB106:02 allele marks individuals at highest risk for this autoimmune process. HLA-DQB1*06:02 negative hypersomnia — sometimes called essential hypersomnia — is, by definition, not narcolepsy type 1. It represents a form of excessive daytime sleepiness in which the autoimmune orexin-deficiency mechanism is not involved. The genetic drivers of this phenotype are therefore expected to be different from NT1, providing an opportunity to study alternative biological pathways underlying sleep excess.
The genetics behind HLA-DQB1*06:02 negative hypersomnia
Because HLA-DQB1*06:02 negative hypersomnia is a narrower and less studied phenotype than narcolepsy, genome-wide studies have been limited in sample size. The current genetic dataset reflects early-stage evidence with a small number of candidate genes.
The top-ranked candidate genes by locus-to-gene scoring are:
PTPA (also known as PPP2R4, Protein Phosphatase 2A Activator), ranked first (locus-to-gene score 0.542, high confidence classification), is a regulator of protein phosphatase 2A (PP2A). PP2A is one of the major serine/threonine phosphatases in mammalian cells and plays a critical role in circadian clock function. PP2A dephosphorylates PERIOD proteins — core components of the molecular circadian oscillator — modulating the pace of the clock and thereby affecting the timing of sleep propensity across the 24-hour cycle. PTPA activates PP2A by promoting its methyl-esterification, making it a direct upstream regulator of the phosphorylation state of circadian proteins. Variation at this locus could alter the tempo or amplitude of circadian rhythmicity in ways that affect arousal maintenance and sleep homeostasis.
CRAT (Carnitine O-Acetyltransferase), ranked second (locus-to-gene score 0.190, medium confidence), is a mitochondrial enzyme that catalyzes the reversible transfer of acetyl groups to carnitine, facilitating the transport of acetyl units across the mitochondrial membrane. CRAT plays a key role in mitochondrial energy homeostasis, particularly in neurons that depend on efficient oxidative phosphorylation to maintain arousal states. Disruption of mitochondrial acetyl-CoA handling could influence the energy availability of hypothalamic and brainstem wake-promoting neurons, though the direct link between CRAT variation and hypersomnia biology remains incompletely characterized.
Additional candidate genes in the filtered set include BCL11A (a zinc-finger transcription factor with roles in B cell development), CART (potentially the CARTPT gene, encoding CART neuropeptide involved in appetite, reward, and stress regulation), SPRED1 (a Sprouty-related EVH1 domain-containing protein that inhibits RAS/ERK signaling), and TAS2R1 (a bitter taste receptor with expression beyond the oral cavity including in the gut and airway). The 9-gene filtered set reflects the limited statistical power of the available hypersomnia GWAS cohorts.
What the research says
Two genome-wide studies have investigated this specific hypersomnia subtype.
Khor et al. (2013) — PeerJ — PMID 23646285
"Genome-wide association study of HLA-DQB1*06:02 negative essential hypersomnia." A genome-wide association study specifically in hypersomnia patients who were negative for the narcolepsy-defining HLA allele, identifying candidate loci for the non-autoimmune form of excessive daytime sleepiness. This study established the conceptual and methodological framework for separating essential hypersomnia from narcolepsy type 1 in genetic research.
Miyagawa et al. (2018) — Journal of Human Genetics — PMID 30266950
"A variant at 9q34.11 is associated with HLA-DQB1*06:02 negative essential hypersomnia." Follow-up genetic study identifying a specific chromosomal locus at 9q34.11 associated with this hypersomnia subtype, nominally supporting the PTPA/CRAT region as the primary signal. The 9q34.11 locus contains both PTPA and CRAT, lending convergent support to this genomic region across two independent studies.
The moderate confidence tier reflects the limited sample sizes and single-region evidence base. The PTPA/CRAT signal at 9q34.11 is the most consistent finding across both studies, but replication in larger independent cohorts is needed before this association is considered established. The biology is mechanistically coherent — PP2A and circadian clock regulation are plausible pathways — but phenotypic heterogeneity in the hypersomnia spectrum remains a challenge for genetic studies.
How HLA-DQB1*06:02 negative hypersomnia affects you
Essential hypersomnia that is not explained by narcolepsy type 1 or other secondary causes represents a distinct clinical entity with significant impact on quality of life. Excessive daytime sleepiness impairs cognitive function, occupational performance, safety (particularly driving and operating machinery), and social relationships. Unlike narcolepsy type 1, this form of hypersomnia does not typically involve cataplexy (sudden loss of muscle tone triggered by emotion), but the sleepiness burden can be equally disabling.
The circadian-clock angle suggested by PTPA genetics raises the possibility that some cases of essential hypersomnia involve dysregulation of the molecular clock — particularly the pace of the PERIOD protein phosphorylation cycle that determines the circadian period length and the timing of sleep propensity. This contrasts with the orexin-deficiency model of narcolepsy and suggests different therapeutic targets.
Working with your variant profile
Genetic variant data from ExomeDNA reflects population-level GWAS associations for hypersomnia in cohorts with defined HLA status. This data does not constitute a clinical evaluation of sleep function, and the associations are based on early-stage evidence with moderate confidence. Evaluation of hypersomnia requires sleep studies, clinical interview, and HLA typing by qualified sleep medicine specialists.
The genetic signal at PTPA/CRAT is intriguing for its circadian and mitochondrial biology, but the locus-to-gene scores and replication status are modest. Functional studies and larger cohort replication are needed before this signal informs clinical decision-making.
Related traits and genes
HLA-DQB1*06:02 negative hypersomnia sits in the sleep phenotype cluster alongside narcolepsy, insomnia, chronotype, and sleep duration. PTPA/PP2A regulation of the circadian clock links this trait to chronotype genetics (the morning-evening preference that reflects clock period length). The CART neuropeptide system connects to metabolic regulation, appetite, and stress response. BCL11A and SPRED1 are also candidates in leukemia and lymphoma genetics and developmental biology, reflecting the broad expression of genes in the filtered set beyond their sleep-relevant roles.
Frequently asked questions
What does the HLA-DQB1*06:02 qualifier mean for hypersomnia genetics?
HLA-DQB106:02 is present in more than 95% of narcolepsy type 1 patients. By restricting the study to HLA-DQB106:02 negative individuals, researchers exclude narcolepsy type 1 from the cohort. This creates a genetically cleaner phenotype for studying excessive daytime sleepiness caused by mechanisms other than autoimmune orexin neuron loss. The genetic loci identified in HLA-DQB1*06:02 negative hypersomnia are therefore distinct from narcolepsy type 1 genetics.
How does PTPA relate to sleep regulation?
PTPA activates protein phosphatase 2A (PP2A), which dephosphorylates PERIOD proteins — core components of the molecular circadian clock. The rate of PERIOD phosphorylation and dephosphorylation determines the period length of the circadian oscillator, which in turn affects when sleep propensity peaks across the 24-hour cycle. Variation in PTPA could alter PP2A activity in clock neurons, potentially shifting the timing or amplitude of sleep drive in ways that manifest as excessive sleepiness during waking hours.
Is essential hypersomnia the same as narcolepsy?
No. Narcolepsy type 1 is caused by autoimmune destruction of orexin neurons and is defined by HLA-DQB106:02 positivity and low cerebrospinal fluid orexin levels. Essential hypersomnia (HLA-DQB106:02 negative) lacks these markers and represents a distinct biological entity. It typically does not involve cataplexy and has different genetic underpinnings. The treatment approaches and prognosis also differ between the two conditions.
Why is the evidence for this trait only moderate confidence?
The moderate confidence rating reflects limited sample sizes in the available GWAS cohorts for this specific hypersomnia subtype. Studying HLA-DQB1*06:02 negative hypersomnia requires precise clinical and laboratory phenotyping (including HLA typing), which limits the scale of studies possible. The 9q34.11 locus shows nominally consistent signal across two studies, but genome-wide significance and large-cohort replication have not been achieved. The associated gene count is small (9 filtered genes), reflecting this limited evidence base.
What is the role of CRAT in the context of sleep biology?
CRAT encodes carnitine O-acetyltransferase, a mitochondrial enzyme involved in acetyl-CoA metabolism and fatty acid oxidation. Wake-promoting neurons in the hypothalamus and brainstem require sustained energy production to maintain arousal across the day. CRAT's role in mitochondrial acetyl group handling could theoretically affect the metabolic capacity of these arousal-regulating neurons, though the mechanistic link between CRAT genetic variation and hypersomnia phenotype remains to be established through functional studies.